Westfield Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Westfield Capital Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.7M	Buy	+1,041,191	New	+$37.8M	0.14%	174

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Westfield Capital Management's INDV Position: Q2 2026 in Review

Westfield Capital Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 1,041,191 shares worth $42.7M. The stake represents 0.14% of the portfolio and ranks #174 among its holdings.

199 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Westfield Capital Management held 1,041,191 shares of Indivior Pharmaceuticals worth $42.7M as of Q2 2026.
Indivior Pharmaceuticals was a new Westfield Capital Management position in Q2 2026.
Indivior Pharmaceuticals made up 0.14% of Westfield Capital Management's portfolio in Q2 2026, its #174 holding.
199 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.